PULMONARY ARTERIAL HYPERTENSION: REGIONAL HEALTH CARE OPPORTUNITIES
Over the past few decades, there have been significant changes in approaches to the management of patients with pulmonary arterial hypertension (PAH). From the moment when the classification of this disease was first published, new diagnostic capabilities and new drugs have appeared that have improv...
Saved in:
| Main Author: | E. V. Filippov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2021-05-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/6269 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01) -
Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01) -
EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01) -
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
Pulmonary arterial hypertension: challenges and achievements 2021
by: E. A. Rezukhina, et al.
Published: (2022-03-01)